Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Onychomycosis Epidemiology Forecasts

DelveInsight’s ‘Onychomycosis–Epidemiology Forecast—2030’ report delivers an in-depth understanding of onychomycosis, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), China, and Japan.

Geographies Covered

  • The United States
  • EU5
  • China
  • Japan

Study Period: 2018–2030

Onychomycosis Disease Understanding

Onychomycosis is a common fungal nail infection that has been estimated to account for about half of all nail diseases. Although not life-threatening, fungal nail infections are an important public health concern due to their high prevalence, poor response to therapy, and significant clinical, social and financial impact.

 

In Western countries, 80–90% of onychomycosis cases are primarily caused by dermatophytes, with 5–17% due to yeasts and 2–3% due to non-dermatophyte molds. The high prevalence of fungal infections in North America is largely due to the immigration of dermatophytes from other areas of the world, such as West Africa and Southeast Asia.

 

Patients with onychomycosis often complain of nail discoloration, nail separation, brittleness, or thickening that often worsens with time. A history of tinea pedis or hyperhidrosis of the feet is common. Nails affected by onychomycosis may cause local pain, difficulty fitting shoes and employment, social embarrassment, and harm the quality of life.

 

Greater than 50% nail plate involvement, more than three nails involved, or presence of dermatophytosis, requires consideration of systemic therapy. 

Onychomycosis Epidemiology

The Onychomycosis epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every G8 countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Onychomycosis epidemiology segmented as the Diagnosed Prevalent Cases of Onychomycosis, Diagnosed Prevalent Cases of Onychomycosis by Subtypes, Diagnosed Prevalent Cases of Onychomycosis by Severity, and Treated Cases of Onychomycosis. The report includes the prevalent Onychomycosis symptoms in the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), China, and Japan from 2018 to 2030.

Country-wise Onychomycosis Epidemiology

The epidemiology segment also provides the Onychomycosis epidemiology data and findings across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), China, and Japan.

  • The total prevalent population of Onychomycosis in the G8 was 93,633,252 in 2020 and expected to increase for the study period, i.e., 2018–2030.
  • As per the estimates, among the European countries, France had the highest prevalent population of onychomycosis with ~11,369,288 cases, followed by Germany, which had a prevalent population of ~10,053,740 in 2020.

Scope of the Report

  • Onychomycosis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
  • Onychomycosis Epidemiology Report and Model provide an overview of the risk factors and global trends of onychomycosis in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), China, and Japan
  • The report provides insight into the historical and forecasted patient pool of onychomycosis in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), China, and Japan
  • The report helps recognize the growth opportunities in the G8 concerning the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of onychomycosis
  • The report provides the segmentation of the Onychomycosis epidemiology by Prevalent Cases of Onychomycosis in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), China, and Japan
  • The report provides the segmentation of the Onychomycosis epidemiology by severity-specific Prevalent Cases of Onychomycosis in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), China, and Japan

Report Highlights

  • 10-year Forecast of Onychomycosis epidemiology
  • G8 Countries Coverage
  • Total Prevalent Cases of Onychomycosis
  • Prevalent Cases according to segmentation: Subtype-specific Prevalence of Onychomycosis and Severity-specific Prevalence of Onychomycosis

KOL Views

We interview KOLs, and SME’s opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the G8 concerning the patient population about onychomycosis?
  • What are the key findings of Onychomycosis epidemiology across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), China, and Japan, and which type will have the highest number of patients during the forecast period (2018–2030)?
  • What would be the total number of patients with Onychomycosis across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), China, and Japan during the forecast period (2018–2030)?
  • At what CAGR the patient population is expected to grow during the forecast period (2018–2030)?
  • What are the disease risk, burden, and unmet needs of onychomycosis?
  • What are the currently available treatments for onychomycosis?

Reasons to buy

The Onychomycosis Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Onychomycosis market
  • Quantify patient populations in the global Onychomycosis market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Onychomycosis therapeutics in each of the markets covered
  • Understand the magnitude of the Onychomycosis population by its Prevalence cases
  • Understand the magnitude of the Onychomycosis population by its Subtype-specific cases
  • Understand the magnitude of the Onychomycosis population by its Severity-specific cases
  • The Onychomycosis epidemiology report and model was written and developed by Masters and PhD level epidemiologists
  • The Onychomycosis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Onychomycosis Market Overview at a Glance

3.1. Market Share (%) Distribution of Onychomycosis in 2018

3.2. Market Share (%) Distribution of Onychomycosis in 2030

4. Executive Summary of Onychomycosis

5. Disease Background and Overview

5.1. Introduction

5.2. Etiology and Risk Factors

5.3. Pathophysiology

5.4. Types

5.5. Clinical Aspects

5.6. Clinical Presentation and Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. G8 Total Prevalent Patient Population of Onychomycosis

6.3. Assumption and Rationale

6.4. The United States

6.4.1. Diagnosed Prevalent Cases of Onychomycosis

6.4.2. Diagnosed Prevalent Cases of Onychomycosis by subtype

6.4.3. Diagnosed Prevalence of Onychomycosis by Severity

6.4.4. Treated cases of Onychomycosis

6.5. EU5

6.5.1. Germany

6.5.1.1. Diagnosed Prevalent Cases of Onychomycosis

6.5.1.2. Diagnosed Prevalent Cases of Onychomycosis by Subtype

6.5.1.3. Diagnosed Prevalent Cases of Onychomycosis by Severity

6.5.1.4. Treated cases of Onychomycosis

6.5.2. France

6.5.2.1. Diagnosed Prevalent Cases of Onychomycosis

6.5.2.2. Diagnosed Prevalent Cases of Onychomycosis by Subtypes

6.5.2.3. Diagnosed Prevalent Cases of Onychomycosis by Severity

6.5.2.4. Treated Cases of Onychomycosis

6.5.3. Italy

6.5.3.1. Diagnosed Prevalent Cases of Onychomycosis

6.5.3.2. Diagnosed Prevalent Cases of Onychomycosis by Subtypes

6.5.3.3. Diagnosed Prevalent Cases of Onychomycosis by Severity

6.5.3.4. Treated Cases of Onychomycosis

6.5.4. Spain

6.5.4.1. Diagnosed Prevalent Cases of Onychomycosis

6.5.4.2. Diagnosed Prevalent Cases of Onychomycosis by Subtypes

6.5.4.3. Diagnosed Prevalent Cases of Onychomycosis by Severity

6.5.4.4. Treated Cases of Onychomycosis

6.5.5. United Kingdom

6.5.5.1. Diagnosed Prevalent Cases of Onychomycosis

6.5.5.2. Diagnosed Prevalent Cases of Onychomycosis by Subtypes

6.5.5.3. Diagnosed Prevalent Cases of Onychomycosis by Severity

6.5.5.4. Treated Cases of Onychomycosis

6.6. Japan

6.6.1. Diagnosed Prevalent Cases of Onychomycosis

6.6.2. Diagnosed Prevalent Cases of Onychomycosis by Subtypes

6.6.3. Diagnosed Prevalent Cases of Onychomycosis by Severity

6.6.4. Treated Cases of Onychomycosis

6.7. China

6.7.1. Diagnosed Prevalent Cases of Onychomycosis

6.7.2. Diagnosed Prevalent Cases of Onychomycosis by Subtypes

6.7.3. Diagnosed Prevalent Cases of Onychomycosis by Severity

6.7.4. Treated Cases of Onychomycosis

7. Appendix

7.1. Bibliography

7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

List of Table

Table 1: Summary of Onychomycosis, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Prevalent Patient Population of Onychomycosis in the G8 (2018–2030)

Table 3: Diagnosed Prevalent Cases of Onychomycosis in the US (2018–2030)

Table 4: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in the US (2018–2030)

Table 5: Diagnosed Prevalent Cases of Onychomycosis by Severity in the US (2018–2030)

Table 6: Treated Cases of Onychomycosis in the US (2018–2030)

Table 7: Diagnosed Prevalent Cases of Onychomycosis in Germany (2018–2030)

Table 8: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in Germany (2018–2030)

Table 9: Diagnosed Prevalent of Onychomycosis by Severity in Germany (2018–2030)

Table 10: Treated Cases of Onychomycosis in Germany (2018–2030)

Table 11: Diagnosed Prevalent Cases of Onychomycosis in France (2018–2030)

Table 12: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in France (2018–2030)

Table 13: Diagnosed Prevalent Cases of Onychomycosis by Severity in France (2018–2030)

Table 14: Treated Cases of Onychomycosis in France (2018–2030)

Table 15: Diagnosed Prevalent Cases of Onychomycosis in Italy (2018–2030)

Table 16: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in Italy (2018–2030)

Table 17: Diagnosed Prevalent Cases of Onychomycosis by Severity in Italy (2018–2030)

Table 18: Treated Cases of Onychomycosis in Italy (2018–2030)

Table 19: Diagnosed Prevalent Cases of Onychomycosis in Spain (2018–2030)

Table 20: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in Spain (2018–2030)

Table 21: Diagnosed Prevalent Cases of Onychomycosis by Severity in Spain (2018–2030)

Table 22: Treated Cases of Onychomycosis in Spain (2018–2030)

Table 23: Diagnosed Prevalent Cases of Onychomycosis in the UK (2018–2030)

Table 24: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in the UK (2018–2030)

Table 25: Diagnosed Prevalent Cases of Onychomycosis by Severity in the UK (2018–2030)

Table 26: Treated Cases of Onychomycosis in the UK (2018–2030)

Table 27: Diagnosed Prevalent Cases of Onychomycosis in Japan (2018–2030)

Table 28: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in Japan (2018–2030)

Table 29: Diagnosed Prevalent Cases of Onychomycosis by Severity in Japan (2018–2030)

Table 30: Treated Cases of Onychomycosis in Japan (2018–2030)

Table 31: Diagnosed Prevalent Cases of Onychomycosis in China (2018–2030)

Table 32: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in China (2018–2030)

Table 33: Diagnosed Prevalent Cases of Onychomycosis by Severity in China (2018–2030)

Table 34: Treated Cases of Onychomycosis in China (2018–2030)

List of Figures

Figure 1: Prevalent Cases of Onychomycosis in the G8 Countries (2018–2030)

Figure 2: Diagnosed Prevalent Cases of Onychomycosis in the US (2018–2030)

Figure 3: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in the US (2018–2030)

Figure 4: Diagnosed Prevalent Cases of Onychomycosis by Severity in the US (2018–2030)

Figure 5: Treated Cases of Onychomycosis in the US (2018–2030)

Figure 6: Diagnosed Prevalent Cases of Onychomycosis in Germany (2018–2030)

Figure 7: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in Germany (2018–2030)

Figure 8: Diagnosed Prevalent Cases of Onychomycosis by Severity in Germany (2018–2030)

Figure 9: Treated Cases of Onychomycosis in Germany (2018–2030)

Figure 10: Diagnosed Prevalent Cases of Onychomycosis in France (2018–2030)

Figure 11: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in France (2018–2030)

Figure 12: Diagnosed Prevalent Cases of Onychomycosis by Severity in France (2018–2030)

Figure 13: Treated Cases of Onychomycosis in France (2018–2030)

Figure 14: Diagnosed Prevalent Cases of Onychomycosis in Italy (2018–2030)

Figure 15: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in Italy (2018–2030)

Figure 16: Diagnosed Prevalent Cases of Onychomycosis by Severity in Italy (2018–2030)

Figure 17: Treated Cases of Onychomycosis in Italy (2018–2030)

Figure 18: Diagnosed Prevalent Cases of Onychomycosis in Spain (2018–2030)

Figure 19: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in Spain (2018–2030)

Figure 20: Diagnosed Prevalent Cases of Onychomycosis by Severity in Spain (2018–2030)

Figure 21: Treated Cases of Onychomycosis in Spain (2018–2030)

Figure 22: Diagnosed Prevalent Cases of Onychomycosis in the UK (2018–2030)

Figure 23: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in the UK (2018–2030)

Figure 24: Diagnosed Prevalent Cases of Onychomycosis by Severity in the UK (2018–2030)

Figure 25: Treated Cases of Onychomycosis in the UK (2018–2030)

Figure 26: Diagnosed Prevalent Cases of Onychomycosis in Japan (2018–2030)

Figure 27: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in Japan (2018–2030)

Figure 28: Diagnosed Prevalent Cases of Onychomycosis by Severity in Japan (2018–2030)

Figure 29: Treated Cases of Onychomycosis in Japan (2018–2030)

Figure 30: Diagnosed Prevalent Cases of Onychomycosis in China (2018–2030)

Figure 31: Diagnosed Prevalent Cases of Onychomycosis by Subtypes in China (2018–2030)

Figure 32: Diagnosed Prevalent Cases of Onychomycosis by Severity in China (2018–2030)

Figure 33: Treated Cases of Onychomycosis in China (2018–2030)

Forward to Friend

Need A Quote